The company's expertise in T cell engagement and T cell receptor biology has led to the creation of a unique approach using TCR Fusion Construct T cells (TRuC-T cells) that recognize and kill cancer cells by harnessing the entire TCR signaling complex, independent of human leukocyte antigens (HLA). TCR2 Therapeutics Inc is a clinical-stage cell therapy company focused on developing a pipeline of novel T cell therapies for patients with solid tumors. The company has scientific operations in Cambridge, Massachusetts and collaborates with top-tier academic laboratories around the world to leverage best-in-class technologies.